Xbrane Biopharma AB (XBRANE) Stock Statistics & Valuation Metrics

Xbrane Biopharma AB has a market cap or net worth of kr427.48M. The enterprise value is kr486.49M.

Xbrane Biopharma AB has 1,532,190,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xbrane Biopharma AB’s return on equity (ROE) is -1.28 and return on invested capital (ROIC) is -56.94%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Xbrane Biopharma AB had revenue of 198.70M and earned -266.22M in profits. Earnings per share was -0.22.

In the last 12 months, operating cash flow was -89.16M and capital expenditures -75.76M, giving a free cash flow of -164.92M billion.

Xbrane Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xbrane Biopharma AB upcoming earnings date is Aug 26, 2025, TBA (Confirmed).

Xbrane Biopharma AB as a current ratio of 1.13, with Debt / Equity ratio of 69.18%

In the past 12 months, Xbrane Biopharma AB has paid 11.59M in taxes.

Xbrane Biopharma AB EV to EBITDA ratio is -1.46, with an EV/FCF ratio of -1.43.

Xbrane Biopharma AB has kr24.71M in cash and marketable securities with kr149.60M in debt, giving a net cash position of kr124.89M billion.

Gross margin is 80.66%, with operating margin of -109.67%, and net profit margin of -133.98%.

The average price target for Xbrane Biopharma AB is ―, which is 11.43% higher than the current price. The consensus rating is Hold